Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

A Randomized Phase II Trial of ASTX727 and Venetoclax Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

NCT ID: NCT06672146Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-11

Summary

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help more patients with the IDH2 gene get rid of AML. ASTX727 is a fixed-dose formulation of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Enasidenib works by stopping the growth and spread of tumor cells that have the IDH2 mutation. Giving ASTX727 and venetoclax plus enasidenib may work better in treating AML patients with the IDH2 mutation.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the safety of decitabine and cedazuridine (ASTX727) + venetoclax + enasidenib (Arm 2) before initiating randomization. II. To compare the rate of measurable residual disease (MRD) negative complete remission (CR) based on multiparameter flow cytometry (MFC) after two cycles of treatment in older adults (or unfit adults age 18 or older) with IDH2 mutated Acute Myeloid Leukemia (AML) who receive ASTX727, venetoclax, and enasidenib versus ASTX727 and venetoclax alone. SECONDARY OBJECTIVES: I. To estimate the composite remission rate (CR + complete remission with incomplete count recovery \[CRi\] + complete remission with partial hematologic recovery \[CRh\]), relapse-free survival (RFS), event-free survival (EFS), duration of response (DOR), and overall survival (OS) of participants by treatment arm. II. To estimate IDH2 mutated variant allele frequency, flow cytometry MRD, and molecular MRD after two cycles of therapy in participants' bone marrow aspirates and blood by treatment arm. III. To estimate remission rates (CR with and without MRD \[MFC and molecular MRD\], CRh and CRi), and to estimate the rates of hematologic improvement by treatment arm. IV. To estimate the frequency and severity of adverse events by treatment arm. V. To evaluate the association between MFC and molecular MRD after two cycles of protocol treatment with the outcomes RFS and OS (landmarked by date of MRD measurement) by treatment arm. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive ASTX727 orally (PO) once daily (QD) on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. ARM 2: Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial. After completion of study treatment, patients are followed up every month for the first year, every 2 months for the second year, every 3 months for the third year, and every 6 months until 5 years after registration or death.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

  • DrugDecitabine and Cedazuridine

    Given PO

  • DrugEnasidenib

    Given PO

  • DrugVenetoclax

    Given PO

Outcome measures

Primary

  • Minimal residual disease negative (MRDneg) complete remission (CR) rate

    A randomized design will be used to compare binary endpoints in two arms with a single interim futility analysis. For the final analysis, a 2-sample proportion z-test will be used to compare the MRDneg-CR rates between arms with a two-sided alpha of 20%.

    Time frame: Baseline to 5 years

Secondary

  • Relapse-free survival (RFS)

    Time frame: Baseline to 5 years

  • Event-free survival

    Time frame: Baseline to 5 years

  • Duration of response

    Time frame: Baseline to 5 years

  • OS

    Time frame: Baseline to 5 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Participants must have been registered to the MYELOMATCH Master Screening and Reassessment Protocol prior to consenting to this study. Participants must have disease with a detectable IDH2 mutation based on central testing through the MYELOMATCH and be assigned to this clinical trial via MATCHBox prior to registration to this study * Note: Pre-enrollment/diagnosis labs must have already been performed under MYELOMATCH * Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) defined by having ≥ 20% blasts in the bone marrow and/or peripheral blood, excluding acute promyelocytic leukemia (APL) with PML-RARA * Participants must not be receiving or planning to receive any other investigational agents while on protocol therapy * Participants must not have received prior therapy for AML or myelodysplastic syndrome (MDS) and/or myeloproliferative neoplasm (MPN) with the exception of hydroxyurea, all-trans retinoic acid (ATRA), colony-stimulating factors, erythropoiesis-stimulating agents, immunosuppressive therapy, intrathecal chemotherapy, a single dose of cytarabine for cytoreduction, and/or leukapheresis * Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction. The use of prior hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide are allowed. Participants may receive hydroxyurea prior to treatment assignment on this substudy for cytoreduction but must agree to discontinue hydroxyurea prior to beginning treatment on this substudy * White blood cell (WBC) must be \< 25 x 10\^9/L. Hydroxyurea, leukapheresis, and cytarabine \< 1 g/m\^2 are permitted to control the WBC prior to enrollment and initiation of protocol-defined therapy but must be stopped prior to initiation of protocol therapy * Participants must be ≥ 60 years old; OR must be ≥ 18 years old and considered not eligible for cytarabine-based induction therapy * Participants must have Zubrod Performance Status of 0-3 as determined by a history and physical (H\&P) exam completed within 14 days prior to registration * Participants must have a complete medical history and physical exam within 14 days prior to registration * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless history of Gilbert's syndrome. Participants with history of Gilbert's syndrome must have total bilirubin ≤ 3 x institutional ULN (within 14 days prior to registration) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 × institutional ULN, unless considered to be elevated due to disease involvement (within 14 days prior to registration) * Participants must have adequate kidney function as evidenced by creatinine clearance ≥ 30mL/min (by Cockcroft Gault) within 14 days prior to registration * Participants must not have a baseline corrected QT interval ≥ 480 msec using Fridericia correction (QTcF). * NOTE: Since older participants are at risk for prolonged QTc and may require supportive care with agents that affect QTc, an electrocardiogram (ECG) is recommended if clinically indicated. If the QTc is prolonged, they should be treated on MYELOMATCH TAP instead of MM1OA-S03 * Participants must have adequate cardiac function in the assessment of their treating physician. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2 or better * Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration * Participants with a known history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to registration, if indicated * Participants with a known history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to registration, if indicated * Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen * Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen * Participants must be able to swallow and retain oral medications and have no known gastrointestinal disorders likely to interfere with absorption of oral medications * Participants must have agreed to have specimens submitted for translational medicine for MRD under MYELOMATCH and specimens must be submitted * Enrollment to this treatment study requires prior enrollment into the myeloMATCH Master Protocol (MYELOMATCH). Participants enrolled in MYELOMATCH will submit bone marrow samples, peripheral blood samples, and buccal swabs to the Molecular Diagnostics Network (MDNet), the Clinical Laboratory Improvement Act (CLIA) laboratory network for myeloMATCH * In addition to the MYELOMATCH specimens, there will be specimens obtained on treatment for this substudy. These specimens will be derived from procedures performed as part of standard assessments in the clinical care and management of AML with material being sent to the MDNet laboratories as specified. After performing the required tests on the specimens, the MDNet laboratories will send the residual material for biobanking and future research. Therefore, participants must be asked for their consent for the biobanking of specimens for future unspecified research. Participants may refuse this, but it is mandatory for sites to ask participants * Participants must be offered the opportunity to participate in specimen banking * NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Study locations (129)

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Sharad Khurana · Principal Investigator

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Sharad Khurana · Principal Investigator

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Recruiting
Site Public Contact · Contact
501-686-8274
Ankur Varma · Principal Investigator

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, 94704

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Ari D. Baron · Principal Investigator

UCSF Medical Center-Parnassus

San Francisco, California, 94143

Recruiting
Site Public Contact · Contact
877-827-3222
Timothy Ferng · Principal Investigator

Mills Health Center

San Mateo, California, 94401

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Ari D. Baron · Principal Investigator

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Hollywood, Florida, 33021

Recruiting
Site Public Contact · Contact
954-265-1847OHR@mhs.net
Stanislav Ivanov · Principal Investigator

Miami Cancer Institute

Miami, Florida, 33176

Recruiting
Site Public Contact · Contact
786-596-2000
Firas El Chaer · Principal Investigator

Memorial Hospital West

Pembroke Pines, Florida, 33028

Recruiting
Site Public Contact · Contact
954-265-4325
Stanislav Ivanov · Principal Investigator

Augusta University Medical Center

Augusta, Georgia, 30912

Recruiting
Site Public Contact · Contact
706-721-2388ga_cares@augusta.edu
Vamsi Kota · Principal Investigator

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Elie G. Dib · Principal Investigator

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Himachandana Atluri · Principal Investigator

University of Illinois

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-355-3046
Noah Birch · Principal Investigator

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Himachandana Atluri · Principal Investigator

NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201

Recruiting
Site Public Contact · Contact
847-570-2109
David L. Grinblatt · Principal Investigator

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Himachandana Atluri · Principal Investigator

NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
847-570-2109
David L. Grinblatt · Principal Investigator

Northwestern Medicine Glenview Outpatient Center

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
312-695-1102
Himachandana Atluri · Principal Investigator

Northwestern Medicine Grayslake Outpatient Center

Grayslake, Illinois, 60030

Recruiting
Site Public Contact · Contact
312-695-1102
Himachandana Atluri · Principal Investigator

NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035

Recruiting
Site Public Contact · Contact
847-570-2109
David L. Grinblatt · Principal Investigator

Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, 60045

Recruiting
Site Public Contact · Contact
cancertrials@northwestern.edu
Himachandana Atluri · Principal Investigator

Loyola University Medical Center

Maywood, Illinois, 60153

Recruiting
Site Public Contact · Contact
708-226-4357
Stephanie B. Tsai · Principal Investigator

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Northwestern Medicine Orland Park

Orland Park, Illinois, 60462

Recruiting
Site Public Contact · Contact
nctnprogram_rhlccc@northwestern.edu
Himachandana Atluri · Principal Investigator

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Himachandana Atluri · Principal Investigator

UChicago Medicine Northwest Indiana

Crown Point, Indiana, 46307

Recruiting
Site Public Contact · Contact
855-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

University of Kansas Clinical Research Center

Fairway, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Kenneth Byrd · Principal Investigator

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Kenneth Byrd · Principal Investigator

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Kenneth Byrd · Principal Investigator

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-562-3429
Mohamed M. Hegazi · Principal Investigator

UofL Health Medical Center Northeast

Louisville, Kentucky, 40245

Recruiting
Site Public Contact · Contact
502-852-2755ctoinfo@louisville.edu
Mohamed M. Hegazi · Principal Investigator

Our Lady of the Lake Physician Group

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Nakhle S. Saba · Principal Investigator

Our Lady of The Lake

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659
Nakhle S. Saba · Principal Investigator

MaineHealth Cancer Care and IV Therapy - Brunswick

Brunswick, Maine, 04011

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

Mid Coast Hospital

Brunswick, Maine, 04011

Recruiting
Site Public Contact · Contact
888-823-5923ctsucontact@westat.com
Pamela Egan · Principal Investigator

MaineHealth Maine Medical Center - Portland

Portland, Maine, 04102

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

MaineHealth Maine Medical Center- Scarborough

Scarborough, Maine, 04074

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

MaineHealth Cancer Care and IV Therapy - South Portland

South Portland, Maine, 04106

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

Tufts Medical Center

Boston, Massachusetts, 02111

Recruiting
Site Public Contact · Contact
617-636-5000ContactUsCancerCenter@TuftsMedicalCenter.org
Andreas K. Klein · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Elie G. Dib · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Elie G. Dib · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Elie G. Dib · Principal Investigator

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Henry Ford Hospital

Detroit, Michigan, 48202

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

OSF Saint Francis Hospital and Medical Group

Escanaba, Michigan, 49829

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Cancer Hematology Centers - Flint

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Elie G. Dib · Principal Investigator

Genesee Hematology Oncology PC

Flint, Michigan, 48503

Suspended

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Elie G. Dib · Principal Investigator

Allegiance Health

Jackson, Michigan, 49201

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Elie G. Dib · Principal Investigator

Henry Ford Medical Center-Columbus

Novi, Michigan, 48377

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Elie G. Dib · Principal Investigator

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Elie G. Dib · Principal Investigator

Mercy Hospital

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Recruiting
Site Public Contact · Contact
218-786-3308
Bret E. Friday · Principal Investigator

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Saint Barnabas Medical Center

Livingston, New Jersey, 07039

Recruiting
Site Public Contact · Contact
973-322-2934joanne.loeb@rwjbh.org
Neil D. Palmisiano · Principal Investigator

Monmouth Medical Center

Long Branch, New Jersey, 07740

Recruiting
Site Public Contact · Contact
732-923-6564mary.danish@rwjbh.org
Neil D. Palmisiano · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Recruiting
Site Public Contact · Contact
732-235-7356
Neil D. Palmisiano · Principal Investigator

Community Medical Center

Toms River, New Jersey, 08755

Recruiting
Site Public Contact · Contact
732-557-8294Lennette.Gonzales@rwjbh.org
Neil D. Palmisiano · Principal Investigator

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Recruiting
Site Public Contact · Contact
505-925-0348HSC-ClinicalTrialInfo@salud.unm.edu
Charles Foucar · Principal Investigator

Roswell Park Cancer Institute

Buffalo, New York, 14263

Recruiting
Site Public Contact · Contact
800-767-9355askroswell@roswellpark.org
Eunice S. Wang · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Paul M. Barr · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Recruiting
Site Public Contact · Contact
800-804-9376
Brittany K. Ragon · Principal Investigator

Duke University Medical Center

Durham, North Carolina, 27710

Recruiting
Site Public Contact · Contact
888-275-3853
Harry P. Erba · Principal Investigator

East Carolina University

Greenville, North Carolina, 27834

Recruiting
Site Public Contact · Contact
252-744-1015eubankss@ecu.edu
Darla K. Liles · Principal Investigator

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157

Recruiting
Site Public Contact · Contact
336-713-6771
Matthew J. Wieduwilt · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Manu Pandey · Principal Investigator

Oregon Health and Science University

Portland, Oregon, 97239

Suspended

Geisinger Medical Center

Danville, Pennsylvania, 17822

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Lindsay Wilde · Principal Investigator

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-647-8073
Annie P. Im · Principal Investigator

Geisinger Wyoming Valley/Henry Cancer Center

Wilkes-Barre, Pennsylvania, 18711

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

Rhode Island Hospital

Providence, Rhode Island, 02903

Recruiting
Site Public Contact · Contact
401-444-1488
John L. Reagan · Principal Investigator

Prisma Health Cancer Institute - Spartanburg

Boiling Springs, South Carolina, 29316

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Easley

Easley, South Carolina, 29640

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Butternut

Greenville, South Carolina, 29605

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Faris

Greenville, South Carolina, 29605

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Eastside

Greenville, South Carolina, 29615

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Greer

Greer, South Carolina, 29650

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Seneca

Seneca, South Carolina, 29672

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Paul J. Shami · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Keri R. Maher · Principal Investigator

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Recruiting
Site Public Contact · Contact
608-775-2385cancerctr@gundersenhealth.org
David E. Marinier · Principal Investigator

William S Middleton VA Medical Center

Madison, Wisconsin, 53705

Recruiting
Site Public Contact · Contact
608-256-1901
Christopher D. Fletcher · Principal Investigator

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
414-805-3666
Guru Subramanian Guru Murthy · Principal Investigator

Saint Vincent Hospital Cancer Center at Oconto Falls

Oconto Falls, Wisconsin, 54154

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Sheboygan

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Sheboygan Physicians Group

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Adedayo A. Onitilo · Principal Investigator

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Adedayo A. Onitilo · Principal Investigator